Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology.

Autor: Pontremoli R; Università degli Studi and I.R.C.C.S. Ospedale Policlinico San Martino, Viale Benedetto XV 6, 16132, Genoa, Italy. roberto.pontremoli@unige.it., Bellizzi V; Division of Nephrology, Dialysis and Transplantation, University Hospital 'San Giovanni di Dio e Ruggi d'Aragona', Via San Leonardo, 84131, Salerno, Italy., Bianchi S; Nephrology and Dialysis Complex Operative Unit, Department of Internal Medicine, ASL Toscana Nordovest, Livorno, Italy., Bigazzi R; Nephrology and Dialysis Complex Operative Unit, Department of Internal Medicine, ASL Toscana Nordovest, Livorno, Italy., Cernaro V; Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy., Del Vecchio L; Department of Nephrology and Dialysis, A. Manzoni Hospital, ASST Lecco, Lecco, Italy., De Nicola L; Nephrology Division, Department of Advanced Medical and Surgical Sciences, University of Campania 'L. Vanvitelli', Piazza Miraglia, 80138, Naples, Italy., Leoncini G; Università degli Studi and I.R.C.C.S. Ospedale Policlinico San Martino, Viale Benedetto XV 6, 16132, Genoa, Italy., Mallamaci F; Nephrology, Dialysis and Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy.; CNR-IFC, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension, Nefrologia-Ospedali Riuniti, 89100, Reggio Calabria, Italy., Zoccali C; Nephrology, Dialysis and Transplantation Unit, Ospedali Riuniti, Reggio Calabria, Italy., Buemi M; Unit of Nephrology and Dialysis, Department of Clinical and Experimental Medicine, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
Jazyk: angličtina
Zdroj: Journal of nephrology [J Nephrol] 2020 Jun; Vol. 33 (3), pp. 417-430. Date of Electronic Publication: 2020 Feb 17.
DOI: 10.1007/s40620-020-00707-2
Abstrakt: Chronic kidney disease (CKD) represents a major public health issue worldwide and entails a high burden of cardiovascular events and mortality. Dyslipidaemia is common in patients with CKD and it is characterized by a highly atherogenic profile with relatively low levels of HDL-cholesterol and high levels of triglyceride and oxidized LDL-cholesterol. Overall, current literature indicates that lowering LDL-cholesterol is beneficial for preventing major atherosclerotic events in patients with CKD and in kidney transplant recipients while the evidence is less clear in patients on dialysis. Lipid lowering treatment is recommended in all patients with stage 3 CKD or worse, independently of baseline LDL-cholesterol levels. Statin and ezetimibe are the cornerstones in the management of dyslipidaemia in patients with CKD, however alternative and emerging lipid-lowering therapies may acquire a central role in near future. This position paper endorsed by the Italian Society of Nephrology aims at providing useful information on the topic of dyslipidaemia in CKD and at assisting decision making in the management of these patients.
Databáze: MEDLINE
Externí odkaz: